NexMed, Inc. (NEXM) Gets $3.5 Million from Novartis
NexMed, Inc., a New Jersey based pharmaceutical and medical technology company, will receive $3.5 million from Swiss pharmaceutical giant Novaris, for fulfilling patent and enrollment milestones as part of a product agreement originally signed in 2005. NexMed announced today that they have received a Notice of Allowance from the patent office for its patent application entitled “Antifungal Nail Coat and Method of Use”. A Notice of Allowance indicates that all the basic steps of a patent application process are completed. The patent is for a topical application of terbinafine formulated with NexACT® for the treatment of onychomycosis, a fungal infection…